Last Updated: June 23, 2026

CLINICAL TRIALS PROFILE FOR RESMINOSTAT

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Resminostat

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00943449 ↗	4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma	Completed	4SC AG	Phase 2	The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.
NCT01037478 ↗	Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma	Completed	4SC AG	Phase 2	The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.
NCT01277406 ↗	4SC-201 (Resminostat) in Advanced Colorectal Carcinoma	Completed	4SC AG	Phase 1/Phase 2	The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.
NCT02400788 ↗	Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)	Completed	Yakult Honsha Co., LTD	Phase 1/Phase 2	The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Resminostat

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Sezary Syndrome	2
Hepatocellular Carcinoma	2
Mycosis Fungoides	2
Advanced Colorectal Carcinoma	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Carcinoma	3
Sezary Syndrome	2
Mycosis Fungoides	2
Carcinoma, Hepatocellular	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Resminostat

Trials by Country

Map
Table

Trials by Country
Location	Trials
Germany	3
United Kingdom	2
Italy	2
Poland	2
Japan	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Resminostat

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	3
Phase 1/Phase 2	2
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	1
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Resminostat

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
4SC AG	5
Yakult Honsha Co., LTD	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.